Orgenesis Inc.
About Us | Market | Technology | Investors
News | Contact
Home | Site Map | RSS Feeds

OTCBB: ORGS

0.90 0.00 (0.00%) | May 19, 2013
  • About Us
    • Profile
    • Corporate
    • Officers
    • Directors
    • Advisory Board
    • Committees
  • Market
    • Overview
    • Diabetes
    • Existing Treatments
    • Our Opportunity
  • Technology
    • Concept
    • Product
    • Treatment
    • Development
    • Clinical Trials
    • Articles
    • Risk Factors
  • Investors
    • Share Price
    • SEC Filings
    • Presentations
    • News Releases
  • News
    • News Releases
    • Events
    • Media
    • RSS Feeds
  • Contact
    • Company
    • News Alert
    • Trials
    • Careers
  •  

Investors

  • Share Price
  • SEC Filings
    • XBRL Filings
  • Presentations
  • News Releases

SEC Filings

logo-sec.gif

Complete company filings may be found by viewing the SEC’s EDGAR website.

D - Notice of Exempt Offering of Securities

2013-05-14

8-K - Current report

2013-05-09

10-Q - Quarterly report [Sections 13 or 15(d)]

2013-04-15

8-K - Current report

2013-04-09

8-K - Current report

2013-03-26


Section 16 Filings

4 - Statement of changes in beneficial ownership of securities

2013-02-28

3 - Initial statement of beneficial ownership of securities

2013-02-28

3/A [Amend] - Initial statement of beneficial ownership of securities

2013-02-14

4 - Statement of changes in beneficial ownership of securities

2013-02-04

3/A [Amend] - Initial statement of beneficial ownership of securities

2013-01-31

4 - Statement of changes in beneficial ownership of securities

2013-01-31

3 - Initial statement of beneficial ownership of securities

2013-01-30

3 - Initial statement of beneficial ownership of securities

2013-01-03

3 - Initial statement of beneficial ownership of securities

2012-04-23

3 - Initial statement of beneficial ownership of securities

2012-04-17


View XBRL Filings


Back to Top

DIABETES -
A MODERN EPIDEMIC

The United States is expected to have an increase of 102 per cent in the diabetic epidemic in 2030
...read more

OUR TECHNOLOGY

An innovative treatment with wide implications using a patient’s own tissue to restore damaged organs
...read more

CLINICAL TRIALS

The initial product is an overall clinical treatment for the diabetic patient...
...read more

About Us

  • Profile
  • Corporate
  • Officers
  • Directors
  • Advisory Board
  • Committees

Market

  • Overview
  • Diabetes
  • Existing Treatments
  • Our Opportunity

Technology

  • Concept
  • Product
  • Treatment
  • Development
  • Clinical Trials
  • Articles
  • Risk Factors

Investors

  • Share Price
  • SEC Filings
  • Presentations
  • News Releases

News

  • News Releases
  • Events
  • Media
  • RSS Feeds

Contact

  • Company
  • News Alert
  • Trials
  • Careers
Orgenesis Inc.
Copyright ® 2013 Orgenesis Inc. All Rights Reserved.
Glossary - Privacy - Terms and Conditions - Site Map